Heamopulse™ - mobile DVT compression device

Overview

The Problem - Deep Vein Thrombosis, the silent killer


Blood clot travels from calf to lungs causing sudden death or lung damage

  • VTE affects 1:1000 people in UK
  • Hospitalisation increases VTE by 8-fold in medical patients and 21-fold in surgical patients
  • 50% of VTE cases in community, related to hospitalisation, causes second largest complication of hospitalisation
  • Financial costs are high and average cost of treating VTE from diagnosis is $14,000
  • First line of treatment is chemoprophylaxis and mechanical compression for high risk and surgical patients

Specific features and benefits


Unique patented sleeve - lightweight and Inobtrusive

Pump specifics

  • Cycle every 30 seconds
  • 8-hour battery life – enabling overnight wear
  • Can be used with or without battery with direct charge – Flexibility in use 2.5 hours full charge
  • Pump can be bed side or direct on sleeve (portable and able to prevent heat discomfort)
  • Low weight 0.24 kg – facilitating mobility
  • Small sleek pump dimensions, low power
  • Low temperature compared with other similar pumps (24oC) – A major complaint from patients

Current issue with existing technologies

  • Attached to expensive pump (£0.5-3k)
  • Lack of enough pumps for COVID patients
  • Patients cannot mobilise without asking nurse to detach
  • 24 sizes of sleeves identified in one hospital trust - issue with supply and storage
  • 24 sizes of sleeves identified in one hospital trust - issue with supply and storage
  • Uncomfortable and noisy making compliance unsatisfactory
  • Sleeves are not wipe clean
  • NEVER EVENTS incidents of patients tripping over the pump connecting wires
  • Currently cannot continue prevention once patient is discharged

Current portable devices are more flexible but:

  • They are integral with the pump and therefore cannot be used for different patients
  • They need significant power to exert compression, therefore generate heat and noise
  • Discarded if contaminated
  • The pumps are bulky
  • Cannot walk whilst being recharged

Advantages of Haemopulse™ over competitors

Patented (2022) sleeve technology causing compression

Market size is significant even if small penetration

An expanding multimillion dollar market

• Haemopulse™ potential revenue based on current estimates

New market opportunities based on IP

Home care

  • Premium product for patients at home
  • DVT Prevention on airlines and care homes
  • Potential application for Chronic Venous Ulcers
  • Haemocap™ multisite for traumatic and post operative wounds
  • Wound binder for infected wounds, cold/heat packs
  • Nearly 63% of VTE’s that occurred within 90 days of surgery were diagnosed after hospital discharge
  • Increased number of day case / outpatient surgery

Summary

  • Haemopulse™ is a unique patented clinically tested compression device with significant advantages over its competitors. There is a large global market for such devices particularly following COVID. The device will reduce DVT and PE, can be used for extended use at home following hospitalisation if necessary.
  • Haemoconcepts have a proven track record. We have developed a unique compression bandage for trauma (Haemocap™) and within 2 years is selling to the NHS.
  • Intermittent portable pneumatic compression devices are an expanding market.
  • Intellectual property allows new opportunities to treat other conditions e.g. wound binder for cold/heat packs, chronic venous ulceration, post surgical site compression.